Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.
2.

Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.

Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK.

Ann Intern Med. 2001 Nov 20;135(10):870-83.

PMID:
11712877
3.

Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.

Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, Hlatky MA.

Ann Intern Med. 1997 Jan 1;126(1):1-12.

PMID:
8992917
4.

Are implantable cardioverter-defribrillators always superior to amiodarone?

Doggrell SA.

Expert Opin Pharmacother. 2003 Nov;4(11):2111-4.

PMID:
14596664
5.

Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction.

Pedretti RF, Migliori GB, Mapelli V, Daniele G, Podrid PJ, Tramarin R.

J Am Coll Cardiol. 1998 Jun;31(7):1481-9.

7.

Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction.

Hlatky MA, Owens DK.

J Am Coll Cardiol. 1998 Jun;31(7):1490-2. No abstract available.

8.

Randomized clinical trials: how long should they last?

Wellens HJ.

Circulation. 2004 Jul 13;110(2):107-8. No abstract available.

9.

Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.

Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA.

Am Heart J. 2002 Sep;144(3):440-8.

PMID:
12228780
10.

Are implantable cardioverter- defibrillators cost-effective?

Naik AM, Peter CT.

Curr Cardiol Rep. 2000 Jul;2(4):341-5.

PMID:
10953269
11.

Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis.

Hallstrom AP, Wyse DG, McAnulty J; CAST; AVID.

J Interv Card Electrophysiol. 2008 Dec;23(3):159-66. doi: 10.1007/s10840-008-9304-4. Epub 2008 Sep 23.

PMID:
18810620
12.
13.

Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone.

Caro JJ, Ward A, Deniz HB, O'Brien JA, Ehreth JL.

Value Health. 2007 Jan-Feb;10(1):13-22.

14.
15.

An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery.

Reddy P, Dunn AB, White CM, Tsikouris JP, Giri S, Kluger J.

Pharmacotherapy. 2002 Jan;22(1):75-80.

PMID:
11794433
16.

Management of cardiac arrest survivors: drugs or devices.

Madan N, Saksena S, Prakash A, Mathew PP.

Indian Heart J. 1995 Jul-Aug;47(4):387-93. Review. No abstract available.

PMID:
8557286
17.

Over-AVID subgroup analysis.

Goldberger JJ, Parker MA, Kadish AH.

J Am Coll Cardiol. 2001 Nov 1;38(5):1586-7. No abstract available.

19.

[Amiodarone or ICD in patients with cardiac insufficiency. SCD-HeFT Study].

Borggrefe M, Wolpert C.

Internist (Berl). 2006 Jan;47(1):89-91. German. No abstract available.

PMID:
16344952
20.

Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death.

Heidenreich PA, Keeffe B, McDonald KM, Hlatky MA.

Am Heart J. 2002 Sep;144(3):422-30.

PMID:
12228778

Supplemental Content

Support Center